Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery
| Autor: | Chad D. Housewright, Hannah Pederson, Cecil Jordan Staples |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Neoplasm Residual Skin Neoplasms medicine.medical_treatment Administration Cutaneous Micrographic surgery Superficial basal cell carcinoma Surgical removal medicine Humans Neoplasm Invasiveness Basal cell carcinoma Aged Retrospective Studies integumentary system business.industry fungi Margins of Excision Retrospective cohort study General Medicine Surgical procedures Mohs Surgery medicine.disease Surgery Treatment Outcome Carcinoma Basal Cell Chemotherapy Adjuvant Female Fluorouracil Neoplasm Recurrence Local Topical Fluorouracil business Adjuvant Follow-Up Studies |
| Zdroj: | Journal of Drugs in Dermatology. 19:485-486 |
| ISSN: | 1545-9616 |
| DOI: | 10.36849/jdd.2020.10.36849/jdd.2020.4811 |
| Popis: | When treating invasive basal cell carcinoma (BCC) with Mohs micrographic surgery (MMS), including infiltrative and nodular subtypes, the goal is complete surgical removal of the tumor. In some cases, after several stages of MMS, residual foci of superficial BCC are noted with no dermal invasive components apparent. Some patients and surgeons have opted for halting surgery and treating residual superficial BCC with adjuvant topical fluorouracil. In this retrospective study, this treatment method is shown to be effective with a recurrence rate of BCC of 3.7% over a mean follow up of 28 months. This treatment method reduces the number of stages of MMS as the surgery is stopped was invasive BCC is removed. This can be beneficial when considering the morbidity of prolonged surgical procedures in frail, elderly patients experiencing surgical fatigue, the cost of additional stages, and the cost of advanced repairs due to enlarging defect size. J Drugs Dermatol. 2020;19(5): doi:10.36849/JDD.2020.4811. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|